Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?
| Autor: | Morgan Rouprêt, Peter McL. Black, Per-Uno Malmstrom |
|---|---|
| Přispěvatelé: | Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of British Columbia (UBC) |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Urology Bladder [SDV]Life Sciences [q-bio] 030232 urology & nephrology [SDV.CAN]Life Sciences [q-bio]/Cancer Unmet needs 03 medical and health sciences 0302 clinical medicine Recurrence Urologi och njurmedicin medicine Urothelial cancer Urology and Nephrology Humans Radiology Nuclear Medicine and imaging Radical surgery Patient summary Bladder cancer Surveillance Progression business.industry Mitomycin C Disease progression Middle Aged medicine.disease 3. Good health Surgery Clinical trial Oncology Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Mutation Neoplasm Female Neoplasm Grading Neoplasm Recurrence Local Non muscle invasive business Immune checkpoint blockade |
| Zdroj: | European Urology Oncology European Urology Oncology, Elsevier, 2019, 2 (6), pp.723-729. ⟨10.1016/j.euo.2019.06.003⟩ |
| ISSN: | 2588-9311 |
| DOI: | 10.1016/j.euo.2019.06.003⟩ |
| Popis: | International audience; Recurrent low-grade Ta tumours, classified as intermediate-risk non-muscle-invasive bladder cancer (NMIBC), have a high risk of recurrence but a low risk of progression. This case presents a 60-yr-old female with intermediate-risk NMIBC who has been treated with sequential courses of mitomycin C followed by bacillus Calmette-Guérin (BCG). She continued to develop multiple episodes of recurrence. The discussion addresses whether the best course is repeat transurethral resection of the bladder with continued monitoring, more of the same intravesical treatments, new methods of applying these treatments, or novel treatments that might involve enrolling the patient in a clinical trial. The biggest unmet need in the field comes from the lack of a molecular marker that could help select patients for aggressive strategies. PATIENT SUMMARY: Following treatment of intermediate-risk non-muscle-invasive bladder cancer with a fairly standard course of intravesical drug therapy, the patient, a relatively young woman, continued to develop recurrences of the bladder cancer. The authors discuss whether the best next course is "more of the same", device-assisted application of these treatments, or perhaps one of the new, still investigatory treatment approaches. Radical surgery (removal of the bladder) should not be necessary unless the recurrences show signs of disease progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect